Generation of RNA Aptamers to the G-Protein-Coupled Receptor for Neurotensin, NTS-1

Daniels, Dion A.; Sohal, Awinder K.; Rees, Stephen Edward; Grisshammer, Reinhard

doi:10.1006/abio.2002.5663

Cited by 39 publications

(23 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aptamers could represent a valuable tool to probe the role of such receptors in normal and pathological tissue and for co-crystallization with receptors for structure determination by X-ray crystallography. As an example of this strategy, aptamers directed against the rat neurotensin receptor NTS-1 were isolated (Daniels et al, 2002). One of the aptamers was characterized in detail and shown to bind to both the rat receptor and the human receptor with nanomolar affinity.…”

Section: Central Regulationmentioning

confidence: 99%

Advances in SELEX and application of aptamers in the central nervous system

Yang¹,

Yang²,

Schluesener³

et al. 2007

Biomolecular Engineering

View full text Add to dashboard Cite

Section: Central Regulationmentioning

confidence: 99%

Advances in SELEX and application of aptamers in the central nervous system

Yang¹,

Yang²,

Schluesener³

et al. 2007

Biomolecular Engineering

View full text Add to dashboard Cite

“…Selection may be carried out against a cell type of interest, with the aim of generating a cell type-specific diagnostic (Hicke et al, 2001;Daniels et al, 2002Daniels et al, , 2003, or payload delivery reagents (Hicke et al, 2001;Homann and Goringer, 2001). Selection may be carried out against a cell type of interest, with the aim of generating a cell type-specific diagnostic (Hicke et al, 2001;Daniels et al, 2002Daniels et al, , 2003, or payload delivery reagents (Hicke et al, 2001;Homann and Goringer, 2001).…”

Section: Cell Surface Targetsmentioning

confidence: 99%

Properties of Therapeutic Aptamers

Cload

McCauley

Keefe

et al. 2006

The Aptamer Handbook

View full text Add to dashboard Cite

Since the invention of the SELEX process and the isolation of the first protein-specific aptamers, parallels to the functional properties of monoclonal antibodies have been drawn. While antibodies have demonstrated utility in a number of settings, their development as therapeutic agents has been long and difficult and it is only in the last 5 years that the field has matured to the stage where one can point to a number of unqualified clinical successes. In many respects, the opportunities for aptamers as therapeutics continue to parallel those for antibodies although the technical challenges have been somewhat different. 2004 was a milestone year for the field with the US Food and Drug Administration (FDA) approval of pegaptanib (Macugenä). In this chapter, we review the properties of aptamers as druglike molecules, highlighting their functional capabilities as target-specific binding agents and our current understanding of how aptamers behave in vivo with respect to distribution, metabolism, and tolerability. The antibody experience provides important lessons for the development of aptamer therapeutics and points the way for future applications which will particularly favor progress with aptamers. Aptamer TargetsThe collected experience of both academic and industry research suggests that aptamers are capable of binding to targets from virtually any protein class (Sullenger and Gilboa, 2002). While early efforts focused largely on nucleic acid-binding targets (e.g.

show abstract

“…Created by an entirely in vitro selection process (SELEX) from libraries of random sequence oligonucleotides, aptamers have been generated against numerous proteins of therapeutic interest, including growth factors, enzymes, immunoglobulins, and receptors (1,2). A typical aptamer is 10-15 kDa in size (i.e., 30-45 nucleotides), binds its target with sub-nanomolar affinity, and discriminates among closely related targets (e.g., will typically not bind other proteins from the same gene family) (3)(4)(5)(6)(7)(8)(9)(10). Aptamers have a number of attractive characteristics for use as therapeutics.…”

Section: Introductionmentioning

confidence: 99%